LPSN · As filed with the SEC
Liveperson cash flow statement, by fiscal year
The statement as Liveperson presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| OPERATING ACTIVITIES: | ||||
| Net loss | (67,233) | (134,273) | (100,435) | (225,747) |
| WildHealth | — | — | — | (23,400) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation expense | 14,256 | 21,989 | 11,854 | 109,638 |
| Depreciation | — | 30,310 | 32,557 | 32,284 |
| Loss on disposal | — | — | — | 0 |
| Depreciation and amortization | 21,975 | — | — | — |
| Reduction of operating lease right-of-use assets | 17 | 4,059 | — | — |
| Amortization of purchased intangible assets and finance leases | 757 | 11,962 | 22,196 | 22,112 |
| Amortization of debt issuance costs and accretion of debt discount | 7,614 | 4,513 | 4,043 | 3,778 |
| Accretion of debt discount on convertible senior notes | — | — | 0 | 0 |
| Impairment of goodwill | 41,595 | 60,551 | 11,895 | — |
| Impairment of intangibles and other assets | 2,108 | 46,872 | 7,974 | — |
| Change in fair value of Warrants | (13,202) | 12,232 | — | — |
| Change in fair value of contingent consideration | 0 | 0 | 4,629 | (8,516) |
| Gain on troubled debt restructuring | (42,429) | — | — | — |
| Gain on debt extinguishment | 0 | (73,083) | (7,200) | — |
| Paid-in-Kind Interest | 15,263 | 5,810 | — | — |
| Allowance for credit losses | 866 | 14,959 | 3,319 | 5,644 |
| Loss (gain) on divestiture | 0 | 558 | (17,591) | — |
| Gain on settlement of leases | — | 0 | 0 | (242) |
| Deferred income taxes | 622 | 623 | 1,046 | (1,161) |
| Equity loss in joint venture | 0 | 0 | 2,264 | — |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 1,160 | 37,548 | 1,457 | (38) |
| Prepaid expenses and other current assets | 3,591 | 7,300 | (3,411) | (5,979) |
| Contract acquisition costs | 10,383 | 3,331 | 4,992 | (6,370) |
| Other assets | 34 | 652 | 1,361 | (153) |
| Accounts payable | — | — | (13,570) | 12,050 |
| Accounts payable, accrued expenses and other current liabilities | (19,823) | (44,518) | 24,343 | 7,485 |
| Deferred revenue | (4,315) | (23,058) | (3,169) | (12,341) |
| Operating lease liabilities | (14) | (4,868) | (523) | (2,638) |
| Other liabilities | (3,660) | 1,401 | (7,796) | 8,093 |
| Net cash used in operating activities | (30,435) | (15,130) | (19,765) | (62,101) |
| INVESTING ACTIVITIES: | ||||
| Purchases of property and equipment, including capitalized internal-use software development costs | (12,088) | (25,142) | (28,657) | (48,486) |
| Proceeds from divestiture | 0 | 0 | 13,819 | — |
| Payments for acquisitions, net of cash acquired | — | 0 | 0 | (3,430) |
| Purchases of intangible assets | (1,639) | (3,074) | (4,004) | (2,680) |
| Repayment of debt acquired in acquisition | — | — | 0 | 0 |
| Investment in joint venture | — | 0 | 0 | (2,264) |
| Net cash used in investing activities | (13,727) | (28,216) | (18,842) | (56,860) |
| FINANCING ACTIVITIES: | ||||
| Payment on settlement of warrants | (1,297) | — | — | — |
| Payment in connection with troubled debt restructuring | (45,000) | — | — | — |
| Proceeds from issuance of 2029 convertible senior notes | 0 | 100,000 | — | 0 |
| 2024 Notes | 0 | (72,492) | — | — |
| 2026 Notes | 0 | (4,901) | — | — |
| Payment of debt issuance costs | 0 | (7,584) | (149,702) | 0 |
| Purchase of capped call option | — | — | — | 0 |
| Principal payments for finance leases | (26) | (401) | (3,330) | (3,734) |
| Proceeds from issuance of common stock in connection with the exercise of options and ESPP | 820 | 350 | 1,890 | 5,573 |
| Repurchase of common stock | — | 0 | 0 | (221) |
| Net cash (used in) provided by financing activities | (45,503) | 14,972 | (151,142) | 1,618 |
| Effect of foreign exchange rate changes on cash and cash equivalents | 1,432 | (1,314) | 465 | (3,981) |
| Net decrease in cash, cash equivalents, and restricted cash | (88,233) | (29,688) | (189,284) | (121,324) |
| Cash, cash equivalents, and restricted cash - beginning of year | 183,237 | 212,925 | 392,198 | 523,532 |
| Cash, cash equivalents, and restricted cash - end of year | 95,004 | 183,237 | 212,925 | 392,197 |
| Supplemental disclosure of other cash flow information: | ||||
| Cash paid for income taxes, net | 1,207 | 1,886 | 1,858 | 3,237 |
| Cash paid for interest | 9,220 | 3,710 | 1,235 | 1,932 |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Issuance of Second Lien Notes due 2029 in connection with troubled debt restructuring | 115,000 | 0 | 0 | (159,407) |
| Issuance of preferred stock in connection with troubled debt restructuring | 20,664 | — | — | — |
| Issuance of common stock in connection with troubled debt restructuring | 49,380 | — | — | — |
| e-bot7 | — | — | 0 | 0 |
| Tenfold | — | — | 0 | 0 |
| VoiceBase | — | — | 0 | — |
| WildHealth | — | 0 | 0 | 17,675 |
| e-bot7 | — | 0 | 0 | 7,362,000 |
| Tenfold | — | 0 | 0 | 6,558,000 |
| VoiceBase | — | 0 | 0 | 16,067,000 |
| WildHealth | — | 0 | 0 | 42,234,000 |
| Purchase of property and equipment and intangible assets in accounts payable | 264 | 1,093 | 2,088 | 1,022 |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 100 | 5,198 | 0 |
| Right-of-use assets obtained in exchange for finance lease liabilities | 0 | 0 | 3,693 | 0 |
| AdvantageTec | — | — | — | 0 |
| Issuance of shares of common stock to settle cash awards | — | 0 | 0 | 17,300 |
| e-bot7 | — | — | — | 351,462 |
| WildHealth | — | — | — | 776,825,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.